Ahmed O. Kaseb - Concepedia

Author

Ahmed O. Kaseb

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

A Cortellini, A Kaseb, A. Kaseb, A. O. Kaseb, A., Kaseb, A.O. Kaseb, Ahmed Kaseb, Ahmed O Kaseb, Ahmed O. Kaseb, Ahmed Omar Kaseb

544

Publications

25.8K

Citations

H-Index

121

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Baylor College of Medicine Massachusetts General Hospital Kindai University The University of Texas Health Science Center at Houston

About

Ahmed O. Kaseb is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and hepatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	54	6.5K
2	Health Sciences	16	21	1.4K
3	Public Health	4	4	224
4	Engineering	2	2	53
5	Biostatistics	2	2	51

Ahmed O. Kaseb

148

Publications

22K

Citations

H-Index

Page 1

	Year	Citations
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma Richard S. Finn, Shukui Qin, Masafumi Ikeda, New England Journal of Medicine	2020	6.8K
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda, Journal of Hepatology HepatologyAtezolizumab Plus BevacizumabUnresectable Hepatocellular CarcinomaMedicineImmunology	2021	1.5K
NASH limits anti-tumour surveillance in immunotherapy-treated HCC Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, Nature	2021	1.2K
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline John D. Gordan, Erin B. Kennedy, Ghassan K. Abou‐Alfa, Journal of Clinical Oncology	2020	601
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma Andrew X. Zhu, Alexander R. Abbas, Marina Ruiz de Galarreta, Nature Medicine MedicineImmunologyMolecular CorrelatesPathologyImmune Checkpoint Inhibitor	2022	580
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial Robin Kate Kelley, Lorenza Rimassa, Ann‐Lii Cheng, The Lancet Oncology	2022	494
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers Rachna T. Shroff, Milind Javle, Lianchun Xiao, JAMA Oncology	2019	460
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial Shukui Qin, Minshan Chen, Ann‐Lii Cheng, The Lancet Surgical OncologyHepatologyMedicinePathologyHigh-risk Hepatocellular Carcinoma	2023	415
Biliary cancer: Utility of next‐generation sequencing for clinical management Milind Javle, Tanios Bekaii‐Saab, Apurva Jain, Cancer	2016	393
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion Li-Chuan Chan, Chia‐Wei Li, Weiya Xia, Journal of Clinical Investigation ImmunologyImmune RegulationPathologyCell DeathPd-l1 Y112 Phosphorylation	2019	364

Page 1